Horizon Investments LLC Reduces Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Horizon Investments LLC trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,131 shares of the medical research company’s stock after selling 123 shares during the period. Horizon Investments LLC’s holdings in Charles River Laboratories International were worth $209,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Fiduciary Financial Group LLC grew its position in shares of Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. M&T Bank Corp increased its position in Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after buying an additional 66 shares in the last quarter. Cornerstone Investment Partners LLC raised its holdings in shares of Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock worth $358,000 after acquiring an additional 69 shares during the last quarter. Finally, Metis Global Partners LLC lifted its position in shares of Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 72 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $191.31.

Charles River Laboratories International Stock Down 4.8 %

CRL opened at $165.51 on Friday. The firm has a 50 day moving average price of $166.49 and a 200 day moving average price of $183.98. The company has a market cap of $8.46 billion, a PE ratio of 1,103.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.46 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).